A suitable time point for quantifying the radiochemical purity of ²²⁵Ac-labeled radiopharmaceuticals.

ABSTRACT:

Background

As ²²⁵Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures. The determination of radiochemical purity (RCP) is an essential QC test. A significant obstacle to RCP testing is the disruption of the secular equilibrium between actinium-225 and its daughter radionuclides during labeling and QC testing. In order to accelerate translation of actinium-225 targeted alpha therapy, we aimed to determine the earliest time point at which the RCP of an ²²⁵Ac-labeled radiopharmaceutical can be accurately quantified.

Results

Six ligands were conjugated to macrocyclic metal chelators and labeled with actinium-225 under conditions designed to gen

SUBMITTER: Kelly JM 

PROVIDER: S-EPMC8688611 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature